UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 333-215027

SHUTTLE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Maryland	46-1747648
(State or Other Jurisdiction of	(I.R.S. Employer
Incorporation or Organization)	Identification No.)

1 Research Court, Suite 450, Rockville, Maryland 20850

(Address of Principal Executive Offices)

(240) 403-4212

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated Filer ☐

Accelerated Filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock, $0.01 par value, as of August 14, 2017 was 45,000,000 shares.

TABLE OF CONTENTS

		Page

PART I – FINANCIAL INFORMATION		2

Item 1.	Financial Statements.	2

	Balance Sheets as of June 30, 2017 (unaudited) and December 31, 2016	2

	Statements of Operations for the six months ended June 30, 2017 and 2016 (unaudited)	3

	Statements of Operations for the three months ended June 30, 2017 and 2016 (unaudited)	4

	Statements of Cash Flows for the six months ended June 30, 2017 and 2016 (unaudited)	5

	Notes to Financial Statements (unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12

Item 3.	Quantitative Disclosures About Market Risks	17

Item 4.	Controls and Procedures	17

PART II - OTHER INFORMATION		18

Item 1.	Legal Proceedings	18

Item 1A.	Risk Factors	18

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18

Item 3.	Defaults Upon Senior Securities	18

Item 4.	Mine Safety Disclosures	18

Item 5.	Other Information	18

Item 6.	Exhibits	18

SIGNATURES		19

PART 1 – FINANCIAL INFORMATION

Item 1.

Financial Statements.

Shuttle Pharmaceuticals, Inc.

Balance Sheets

(Unaudited)

	June 30 December 31
	2017			2016
ASSETS

Current assets
Cash and cash equivalents	$	172,820		$	92,797
Contract receivable		133,548			18,777
Prepaid expenses		6,889			4,353

Total current assets		313,257			115,927

Property and equipment, net		29,082			38,753

Total Assets	$	342,339		$	154,680

LIABILITIES AND STOCK HOLDERS’ EQUITY (DEFICIT)

Current liabilities
Accrued expenses	$	291,906		$	68,527
Accrued interest payable		7,619			3,147
Note payable-related party		83,508			33,610
Advance contract payments		92,502			—

Total current liabilities		475,535			105,284

Long term Liabilities
Convertible notes payable		120,250			120,250

Total liabilities		595,785			225,534

Stockholder’ Equity:
Members equity		—
Stockholders’ equity (deficit)
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2017 and December 31, 2016		—			—
Common stock, $0.01 par value, 100,000,000 shares authorized, 45,000,000 shares issued and outstanding as of June 30, 2017 and December 31, 2016		450,000			450,000
Additional paid-in capital		550,100			550,000
Accumulated deficit		(1,253,546	)		(1,070,854	)
Total Stockholder’s equity (deficit)		(253,446	)		(70,854	)
Total liabilities and stockholders’ equity (deficit)	$	342,339		$	154,680

The Accompanying Notes are an Integral Part of the Financial Statements

Shuttle Pharmaceuticals, Inc.

Statements of Operations

(Unaudited)

	For the six months ended June 30
	2017			2016
Revenue	$	—		$	—
Operating expenses
Research and Development-Net of Contracts		75,392			55,119

General and administrative		102,308			72,195

Loss from Operations		(177,700	)		(127,314	)

Other Income (Expense)
Interest Expense-related party		(580	)		—
Interest Expense Accrued-convertible notes		(4,472	)		—
Interest Income-related party		—			277
Interest Income-other		60			110

Loss before provision for taxes		(182,692	)		(126,927	)

Income tax provision		—			—

Net loss	$	(182,692	)	$	(126,927	)

Basic and diluted Loss per common share	$	(0.00	)	$	(0.00	)

Weighted average common shares outstanding		45,000,000			45,000,000

The Accompanying Notes are an Integral Part of the Financial Statements

Shuttle Pharmaceuticals, Inc.

Statements of Operations

(Unaudited)

	For the three months ended June 30
	2017			2016
Revenue	$	—		$	—
Operating expenses
Research and Development-Net of Contracts		(1,150	)		40,404

General and administrative		76,839			62,259

Loss from Operations		(75,689	)		(102,663	)

Other Income (Expense)
Interest Expense-related party		(212	)		—
Interest Expense accrued-convertible notes		(2,248	)		—
Interest Income-related party		—			132
Interest Income-other		5			10

Net Loss before taxes		(78,144	)		(102,521	)

Income tax provision		—			—

Net loss	$	(78,144	)	$	(102,521	)

Basic and diluted Loss per common share	$	(0.00	)	$	(0.00	)

Weighted average common shares outstanding		45,000,000			45,000,000

The Accompanying Notes are an Integral Part of the Financial Statements

Shuttle Pharmaceuticals, Inc.

Statements of Cash Flows

(Unaudited)

	For the six months ended June 30
	2017			2016
Cash flows from operating activities:
Net Loss	$	(182,692	)	$	(126,927	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation		9,671			6,374
Change in Operating Assets and Liabilities
Contract receivable		(114,771	)		(7,742	)
Advance NIH receivable		92,503			—
Prepaid expenses		(2,536	)		(5,407	)
Accrued interest		4,472			—

Accrued Expenses		223,378			(1,547	)

Net cash provided by (used in) operating activities		30,025			(135,249	)

Cash flow from investing activities:
Repayment of note receivable-related party		—			13,128
Net cash provided by investing activities		—			13,128
Cash flow from financing activities
Capital Contributions		100			20,000
Proceeds from note payable-related party		75,000			—
Repayment of note payable-related party		(25,102	)		—
Net cash provided by financing activities		49,998			20,000

Net increase (decrease) in cash and cash equivalents		80,023			(102,121	)
Cash and cash equivalents at beginning of period		92,797			128,836

Cash and cash equivalents at end of period	$	172,820		$	26,715

Supplemental Disclosure of Cash Flow Information:
Cash paid during year for interest	$	0		$	0
Cash paid during year for taxes	$	0		$	0

The Accompanying Notes are an Integral Part of the Financial Statements

Shuttle Pharmaceuticals, Inc.

Notes to Financial Statements

June 30, 2017

(unaudited)

Note 1

Nature of Organization

Operations

The Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed articles of conversion with the state of Maryland to convert from an LLC to a corporation. In connection with the conversion the Company issued 45,000,000 shares of common stock for the outstanding 100 membership interest prior to the conversion. The Company’s primary purpose is the development and commercialization of unique drugs for the sensitization of cancers and protection of normal tissues, to improve the outcomes of cancer patients receiving radiation therapy. The company has a product (ropidoxuridine) for use with radiation therapy which is the subject of a Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI), a unit of the National Institutes of Health. The company also has obtained an option to rights to a product (doranidazole) for use with radiosurgery, developed by Pola Pharma, a Japanese Pharmaceutical company (“Pola”).

Pola has granted to the Company an exclusive option to license Doranidazole in the U.S. As consideration for this exclusive option, the Company shall grant to Pola a royalty free, fully paid up, perpetual non-exclusive license to use any and all data, results, information and know how generated through activities by the Company during the option period, for licensing, development or commercializing purposes of Doranidazole. The option has not yet been exercised and the Company has incurred no costs to date.

Upon exercise of the option, the Company and Pola have agreed to execute within a reasonable period not to exceed thirty (30) days a license agreement granting the Company exclusive rights to make, have made, use, import, export, offer to sell and sell Doranidazole in the U.S. In the event Shuttle needs the active pharmaceutical ingredient of Doranidazole, API, for their evaluation, Shuttle may purchase API from Pola for a price of US$20,000/kg on “as is” basis up to 10kg. Pola shall be responsible for the preparation, filing, prosecution and maintenance of any and all patent applications and patents related to Doranidazole and its commercialization.

The Company is in the development stage, requiring substantial capital for research, product development and market development activities. The Company has not marketed a commercial product and the Company’s proposed products will require successful clinical testing, regulatory approval and additional investment prior to commercialization. The future success of the Company is dependent on its ability to raise working capital to develop and eventually to manufacture and market its products. There is no assurance that the Company will be able to secure the necessary financing or regulatory approvals to attain successful future operations. Therefore, the predictability of the Company’s future is uncertain.

Note 2

Going Concern

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has not generated any revenues since inception, has incurred losses since its inception and has an accumulated deficit of $1,253,546 at June 30, 2017. The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Management will seek potential business opportunities for merger or acquisition of an existing company. Management, while not especially experienced in matters relating to public company management, will rely upon their own efforts and that of its Board of Directors in accomplishing the business purposes of the Company. Management began in the fourth quarter of 2015 to form new capital in the form of an SEC Regulation D, Rule 506 Private Placement in the amount of 105,000,000 offering shares.

Note 3

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company at June 30, 2017 and the results of operations and cash flows for the periods presented. The results of operations for the six and three months ended June 30, 2017 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited financial statements should be read in conjunction with the financial statements and related notes thereto year ended December 31, 2016 filed with form S-1 on May 5, 2017.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Estimated expenses were made by month based on actual salaries and the approximate overhead, G&A and fringe expenses associated as percentages of the salaries, in addition to the actual supplies expenses and accrued subcontracts expenses spread out over the course of each contract.

Development Stage Company

The company is considered to be in the development stage as defined in ASC 915 “Development Stage Entities.” The company is devoting substantially all of its efforts to the development of its business plans. The company has elected to adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements; and does not present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.

Property and Equipment

Property and equipment are stated at cost. Equipment is depreciated using the straight-line method over the estimated useful lives of the assets. Repair and maintenance costs are expensed as incurred.

Research and Development Expenses

Research and development expenses are charges to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical and regulatory expenses, payroll and other personnel expenses, materials, supplies, and consulting costs.

These expenses are assigned to the clinical project to develop ropidoxuridine in combination with radiation therapy. The SBIR contract covers much of the Phase I clinical trial in advanced GI malignancies.

The research expenses are assigned to the clinical project to develop ropidoxuridine in combination with radiation therapy as a treatment for cancer. Costs that are not covered by the SBIR contract for performing the Phase I contract to determine commercialization feasibility included partial salary support of personnel and consultant to develop a commercialization plan. Costs that are not covered in the Phase II contract effort include business development and partial salary support.

Research expenses related to new drug discovery include partial support of personnel, space, supplies and legal costs. These are preclinical studies and have led to discovery of the candidate lead ATM/HDACi bifunctional agent, an HDAC6 inhibitor and novel formulations of IUdR and IPdR.

The Company has successfully competed for three SBIR contracts from the NIH to support research projects with potential for commercialization. The contract awards are fixed payment in response to quarterly Shuttle invoices and provide non-diluting funds that do not include a repayment obligation. Details on the three contracts follow:

1. Contract #HHSN261201400013C supports “Clinical development of IPdR for Radiosensitization” and consists of a “fast-track” award that includes $191,971 Phase I and $1,428,117 Phase II funding from 9/19/2014 through 9/18/2017. This contract includes a subcontract with Brown University, LifeSpan/Rhode Island Hospital for the performance of a Phase I clinical trial. The Phase I clinical trial of ropidoxuridine and radiation therapy is underway at Lifespan/Rhode Island Hospital. The subcontract sets forth the following technical objectives of the Phase I clinical trial: (i) activate the IPdR IND for the Phase I and PK clinical trial, (ii) obtain approvals for the Phase I and PK clinical protocol; develop efficacy protocols satisfying FDA “Orphan Drug” status and (iii) establish the in-house Company biomarker assays. The subcontract provides for the reimbursement of Lifespan/Rhode Island Hospital’s allowable costs. In accordance with the subcontract, if we receive positive results from the Phase1 clinical trial, we plan to advance to Phase 1b and Phase II clinical trials of using ropidoxuridine in conjunction with RT treatments of patients with brain tumors and soft tissue sarcomas. The subcontract provides for a total amount of $688,818 to be funded in connection with Phase I and Phase II.

2. Contract #HHSN261201600027C supports “Predictive Biomarkers of prostate Cancer Patient Sensitivity for Radiation Late Effects.” This is a $299,502 Phase I award funding research from 9/19/2016 through 9/18/2017. This contract includes a subcontract with Georgetown University for use of Mass Spectrometry core facilities to analyze clinical samples.

3. Contract #HHSN261600038C supports “Cell-based Models for Prostate Cancer Health Disparity Research.” This is a $224,687 Phase I award funding research from 9/19/2016 through 6/18/2017. This contract includes a subcontract with Georgetown University for use of a tissue culture core facility for growing human prostate cells from African-American donors. This contract was completed in its entirety and was closed out on 6/18/2017.

In regards to the accounting treatment for reimbursements US GAAP provides limited guidance on the accounting for government grants received by for-profit companies. We understand that there is more than one acceptable alternative for the accounting treatment – a reduction of costs, a deferred credit to be amortized, revenue, or other income. Due to the terms of the contracts we have entered into the Company concluded that the reimbursements were more akin to a reduction of costs rather than any of the other alternatives to match the contract reimbursements on a systematic basis to the costs that the contract is intended to compensate.

The Company has received a contract from the Department of Health and Human Services to assist with the clinical development of IPdR for radiosensitization. The Company recognizes the amounts received in regards to the contract at fair value when there is reasonable assurance that the contract amount will be received and it is probable that all attaching conditions will be complied with. The Company recognizes the amounts received in accordance with the contract as a reduction of research and development expenses over the periods necessary to match the contract on a systematic basis to the costs that it is intended to compensate. The Company recorded on the balance sheet as contract receivable upon meeting the criteria discussed above until cash is received. During the six months ended June 30, 2017 and 2016, the Company recorded $596,502 and $258,486 in accordance with the contract and during the three months ended June 30, 2017 and 2016, the Company recorded $379,449 and $111,590 in accordance with the contract. which have been recorded as a reduction of research and development expense in the accompanying statement of operations.

Cash and cash equivalents

The Company considers all short-term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents.

Fair Value of Financial Instruments

The carrying amounts of financial instruments such as cash equivalents and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. The Company invests its excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities.

The fair value of financial assets and liabilities is measured under a three-tier fair value hierarchy as follows: Level 1 fair value is determined from observable, quoted prices in active markets for identical assets or liabilities. Level 2 fair value is determined from quoted prices for similar items in active markets or quoted prices for identical or similar items in markets that are not active. Level 3 fair value is determined using the entity’s own assumptions about the inputs that market participants would use in pricing an asset or liability.

Impairment of Long-Lived Assets

The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairments of long-lived assets during years presented.

Income Taxes

Income taxes are accounted for in accordance with ASC 740, Income Taxes (“ASC 740”). The provision for, or benefit from, income taxes is calculated using the asset and liability method, under which deferred tax assets and liabilities are recorded based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are evaluated on a quarterly basis to determine if adjustments to the valuation allowance are required. In accordance with ASC 740, we assess whether a valuation allowance should be established based on the consideration of all available evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. The ultimate realization of deferred tax assets depends primarily on the generation of future taxable income during the periods in which the differences become deductible. The value of our deferred tax assets will depend on applicable income tax rates. Judgment is required in determining the future tax consequences of events that have been recognized in our consolidated financial statements and/or tax returns. Differences between anticipated and actual outcomes of these future tax consequences could have a material impact on our consolidated financial statements.

Convertible Instruments

The Company evaluates and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

Note 4

Property and Equipment

Property and equipment consisted of the following:

		June 30, 2017		December 31, 2016
Office Furniture and equipment	$	7,731	$	7,731
Laboratory equipment		88,064		88,064
		95,795		95,795

Less: accumulated depreciation		66,713		57,042

Property and equipment, net	$	29,082	$	38,753

Depreciation expense of property and equipment for the six months ended June 30, 2017 and 2016 was $9,671 and $6,374 respectively.

The equipment is being depreciated on the straight-line bases over the estimated useful lives of the asset of 4-5 years.

Note 5

Commitments and Contingencies

The Company currently has a lease agreement which allows for the use of a laboratory facility for a monthly payment of $3,685, which was amended on July 1, 2016 to a monthly amount of $3,879 and expires on June 30, 2017. The Company has signed a three month extension that is effective July 1, 2017 through September 31, 2017, for a monthly amount of $3,807.

Note 6

Note payable-Related party

On August 15, 2016, the Company received a loan from a related party in the amount of $50,000. The loan is payable in monthly installments of $4,280 inclusive of interest at 5% per annum until maturity on August 14, 2017. Interest expense incurred on this loan was $580 for the six months ended June 30th, 2017.

On June 30, 2017, the Company received a loan from a related party in the amount of $75,000. The loan is payable in 12 monthly installments of $6,420 inclusive of interest at 5% per annum until maturity on June 30, 2018.

Note 7

Convertible note payable

In August and September 2016, the Company received loans from unrelated parties in the aggregate amount of $120,250. The loans mature two years from the date of issuance, bear interest at 7.5%per annum, and are convertible into the shares of stock at, if at any time prior to the Maturity Date, and if the Company consummates a Sale Event or a Qualified Financing, then, immediately prior to consummation of the Sale Event or the Qualified Financing, the principle amount of and all unpaid accrued interest on this Note shall automatically convert shares at the Conversion Price, which is a 30% discount to the effective per share offering price of the qualified financing.

Note 8

Equity

In connection with the filing of the articles of conversion referred to in note 1 and the articles of incorporation, the Company is authorized to issue 100,000,000 shares of common stock with a par value of $.01 and 5,000,000 shares of preferred stock with a par value of $.01.

On August 12, 2016, in connection with the conversion the Company issued 45,000,000 shares of common stock for the outstanding 100 membership interests of the Company prior to the conversion.

The Company has no outstanding shares of preferred stock at June 30, 2017.

Note 9

Income Taxes

The Company has approximately $380,000 of net operating losses (“NOL”) carried forward to offset taxable income, if any, in future years which begin to expire in fiscal 2036. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized.

Note 10

Subsequent Events

Management has evaluated subsequent events through the date when the financial statements were available to be issued.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

When used in this report, unless otherwise indicated, the terms “the Company,” “Shuttle,” “we,” “us” and “our” refer to Shuttle Pharmaceuticals, Inc.

Note Regarding Forward Looking Statements

This report contains forward-looking statements that reflect our current views about future events. We use the words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Business Overview

Shuttle is a specialty pharmaceutical company founded in 2012, with the goal of becoming the first U.S. pharmaceutical company focused on the development and commercialization of innovative first-in-class drugs for sensitizing cancers to and protecting normal tissue from the effects of RT. The FDA considers new molecular entities as first-in-class, if such drugs like our initial product candidates, use a new and unique mechanism of action for treating a medical condition. Our objective is to improve the outcomes of cancer treatment through RT and reducing its side effects by:

●

sensitizing growing cancer cells, rendering them more susceptible to the effects of RT;

●

sensitizing hypoxic cells in tumors that resist regular RT; and

●

activating the DNA damage response pathway to protect normal cells located near cancers.

To date, we have developed, to clinical stage, small molecule strategies to sensitize growing cancer cells in tumors to conventional RT and to sensitize treatment resistant, hypoxic cancer cells in tumors to large fraction radiation therapy using SBRT. A pre-clinical technology delivery platform using HDAC inhibitors, which are designed to target cancer cells while protecting healthy tissue, further enhances our pipeline. Shuttle has two clinical stages, first in class product candidates that we believe will deliver these benefits in conjunction with our technology platform:

●

Ropidoxuridine, an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties, is our lead “clinical phase” product candidate. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and become more sensitive to the effects of RT. We have received an SBIR contract from the NIH to fund a Phase 1 clinical trial at and in collaboration with Brown University - Lifespan/Rhode Island Hospital to determine safety and the maximum tolerated dose in patients with advanced gastrointestinal cancers. In connection with the trial, NCI has approved the Phase 1 clinical protocol and agreed to provide drug and clinical data management support to Rhode Island Hospital. If we receive positive results from the Phase1 clinical trial, we plan to advance to Phase 1b and Phase 2 clinical trials of using ropidoxuridine in conjunction with RT treatments of patients with brain tumors and soft tissue sarcomas. The Phase 1 clinical trial of ropidoxuridine and radiation therapy is underway at Lifespan/Rhode Island Hospital under subcontract from Shuttle Pharmaceuticals, Inc. Five patients have been entered on trial designed to determine drug safety and the maximum tolerated dose. The clinical trial is supported by funding from the NIH/NCI to Shuttle via an SBIR contract, and a subcontract from Shuttle to Lifespan/RIH. In addition the NIH holds the IND through its Cancer Therapy Evaluation Program (“CTEP”) and supports the clinical trial by providing the drug, ropidoxuridine, and data management through a CRO, Theradex.

Ropidoxuridine, our lead oral “clinical phase” product candidate is a halogenated pyrimidines that is incorporated into DNA by rapidly growing cancer cells resulting in cells that are more sensitive to the effects of radiation therapy. In the Phase 1 clinical trial in progress at Brown University - Lifespan/Rhode Island Hospital we will determine safety and the maximum tolerated dose (MTD) in patients receiving the drug and fractionated radiation therapy. Determination of the MTD in Phase I will allow us to design and execute a subsequent Phase II clinical trial for the endpoints of tumor response as measured by disease free survival and overall survival. The IND for ropidoxuridine (IPdR) was initially filed by Dr. Timothy Kinsella on July 7, 2004, inactivated on February 27, 2008 and subsequently reactivated by the FDA on December 3, 2010.

●

Doranidazole, an injectable hypoxic cell radiation sensitizer, is our second “clinical phase” product candidate. As cancer cells outgrow the blood supply and oxygen availability becomes limiting, regions of hypoxia develop within a tumor. Cancer cells under hypoxic conditions are more resistant to the killing effects of RT. Electron affinic drugs, such as doranidazole are able to reach areas of tumor hypoxia to effect radiation sensitization, thereby offering the potential to improve the outcome of RT treatment by increasing hypoxic cell kill. Unfortunately, first and second generation hypoxic sensitizers used to date have shown neurologic toxicity and little clinical benefit. Doranidazole, which has been developed in Japan by Pola Pharma, has been well-tolerated in clinical studies conducted in Japan and has shown improved survival in a randomized Phase 3 clinical trial of advanced pancreatic cancers, when used in combination with IORT, as opposed to treatment by IORT alone. Shuttle has secured an exclusive option to license Doranidazole for development and commercialization in the U.S. We intend to focus on the use of Doranidazole for treatment of pancreatic, lung and liver cancers in combination with large fraction SBRT, which is radiation therapy administered in large doses over a several day period as opposed to conventional RT, which is generally administered in small daily doses over an extended period of several weeks.

In addition to our two primary product candidates, we are developing and planning to commercialize other cancer radiation sensitizers with radiation protecting properties, which target protecting normal tissue during the administration of RT and other first-in-class products utilizing our HDAC small molecule technology platform.

We have also been two awarded SBIR contracts from the NIH to:

●

develop prostate cancer cell lines from African-American men, who are at higher risk for prostate cancer, with donor matched normal prostate cells, with the goal of establishing 50 prostate cancer cell lines for research aimed at treating prostate cancer in African American men; and

●

develop predictive biomarkers for predicting outcomes for prostate cancer patients following treatment with SBRT.

Results of Operations

Comparison of three months ended June 30, 2016 and June 30, 2017

The following table summarizes the results of our operations for the three months ended June 30, 2016 and 2017:

	For the three months ended June 30,					Increase/
	2016		2017			(Decrease)
Research and development-net of contracts	$	40,404	$	(1,150	)	$	(41,544	)
General and administrative		62,259		76,839			14,583
Other income (expense):
Interest Expense – related party		—		(212	)		(212	)
Interest Expense Accrued – convertible notes		—		(2,248	)		(2,248	)
Interest Income – related party		132		—			(132	)
Interest Income - Other		10		5			(5	)
Total other income (expense)		142		(2,455	)		(2,597	)

Research and Development Expenses-Net of contracts. Research and development expenses-net of contracts were $40,404 for the three months ended June 30, 2016, as compared to $(1,150) for the three months ended June 30, 2017. The decrease of $(41,554) is primarily a result of an increase in wages from $77,502 in the three months ended June 30, 2016 to $102,813 in the three months ended June 30, 2017, and an increase in subcontractor expenses from $27,657 in the three months ended June 30, 2016 to $202,789 in the three months ended June 30, 2017.

General and Administrative Expenses. General and administrative expenses were $62,259 for the three months ended June 30, 2016, as compared to $76,389 for the three months ended June 30, 2017. This increase is primarily due to an increase in Company legal expenses, $11,388 for the three months ended June 30, 2016 as compared to $62,673 for the three months ended June 30, 2017 and accounting expenses, $2,700 for the three months ended June 30, 2016 as compared to $12,840 for the three months ended June 30, 2017.

Consulting expenses were $47,500 for the three months ended June 30, 2016 as compared to $0 for the three months ended June 30, 2017. All other general and administrative expense variations are immaterial.

Other Income (Expense). Other income (expense) was $142 for the three months ended June 30, 2016 which consisted of the interest income on a loan related party and interest earned on a money market account and $(2,455) for the three months ended June 30, 2017, which consisted of $5 for interest income on late remittance from NIH, ($2,248) for interest expense on convertible loans and ($212) interest expense on a loan-related party.

Comparison of six months ended June 30, 2016 and June 30, 2017

The following table summarizes the results of our operations for the six months ended June 30, 2016 and 2017:

	For the six months ended June 30,					Increase/
	2016		2017			(Decrease)
Research and development-net of contracts	$	55,119	$	75,392		$	20,273
General and administrative		72,195		102,308			30,113
Other income (expense):
Interest Expense – related party		—		(580	)		(580	)
Interest Expense Accrued – convertible notes		—		(4,472	)		(4,472	)
Interest Income – related party		277		—			(277	)
Interest Income - Other		110		60			(50)
Total other income (expense)		387		(4,992	)		(5,379	)

Research and Development Expenses-Net of contracts. Research and development expenses-net of contracts was $55,119 for the six months ended June 30, 2016, as compared to $75,392 for the six months ended June 30, 2017. The increase of $20,273 is primarily a result of two additional NIH fixed contracts that became effective in September 2016 and reimbursed the Company based on a pre-determined set payment schedule.

General and Administrative Expenses. General and administrative expenses were $72,195 for the six months ended June 30, 2016, as compared to $102,308 for the six months ended June 30, 2017. This increase is primarily due to an increase in Company legal expenses, $11,388 for the six months ended June 30, 2016 as compared to $73,847 for the six months ended June 30, 2017, and accounting expenses, $4,050 for six months ended June 30, 2016 as compared to $24,161 for the six months ended June 30, 2017.

Company legal and professional expenses increased as the Company continued to utilize legal services for HDAC inhibitor patent work and additional legal and professional fees for the SEC S-1 registration statement. Consulting expenses increased as general Company consulting engagements increased, an orphan drug application was submitted and the consulting company, CHMS, was engaged with to serve as the primary lead in the SEC S-1 application process. Accounting expenses increased primarily due to the SEC S-1 preparation process. All other general and administrative expense variations are immaterial.

Other Income (Expense). Other income (expense) was $387 for the six months ended June 30, 2016 which consisted of the interest income on a loan related party and interest earned from a money market account and $(4,992) for the six months ended June 30, 2017, which consisted of $60 for interest income on late remittance from NIH, ($4,472) for interest expense on convertible loans and ($580) interest expense on a loan-related party.

Liquidity and Capital Resources

As of June 30, 2017, total current assets were $313,257 as compared to $115,927 on December 31, 2016. Total current liabilities as of June 30, 2017 were $475,535 as compared to $105,284 as of December 31, 2016. The increase in current liabilities is due to an increase in accounts payable of $64,019 for the year ended December 31, 2016 as compared to $290,778 for the six months ended June 30, 2017, an increase in advance NIH receivable of $0 for the year ended December 31, 2016 as compared to $92,503 for the six months ended June 30, 2017 and an increase in a note payable-related party of $0 for the year ended December 31, 2016 as compared to $83,508 for the six months ended June 30, 207.

Net cash provided by operating activities was $30,025 in the six months ended June 30, 2017 compared to net cash used of $135,249 for the same period in 2016.

Net of cash provided by investing activities was $0 in the six months ended June 30, 2017 as compared to $13,128 for the same period in 2016. This activity was primarily due to the repayment of a note receivable-related party.

Net cash provided by financing activities in the first six months of 2017 was $49,998 compared to $20,000 in the first six months of 2016.

Our capital needs to date have been met by contributions from existing shareholders, as well as through our private offerings of our securities, SBIR contracts and other grants. We believe that we will continue to expend substantial resources for the foreseeable future on the completion of clinical development and regulatory preparedness of our product candidates, preparations for a commercial launch of our product candidates, if approved, and development of any other current or future product candidates we may choose to further develop. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, obtaining marketing approvals, and, if we are not able to enter into planned collaborations, manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any drug development process is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current product candidates, if approved, or future product candidates, if any.

There can be no assurance that additional financing will be available to the Company when needed, on favorable terms or otherwise. Moreover, any such additional financing may dilute the interests of existing shareholders. The absence of additional financing, when needed, could cause the Company to delay implementation of its business plan in whole or in part, curtail its business activities and seriously harm the Company and its prospects.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3.

Quantitative Disclosures About Market Risks.

As a “smaller reporting company,” we are not required to provide the information required by this Item.

Item 4.

Controls and Procedures.

Management’s Report on Disclosure Controls and Procedures

Our Chief Executive Officer and our Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, as of June 30, 2017 to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms adopted by the Securities and Exchange Commission (the “SEC”), including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (our Principal Executive Officer) and our Chief Financial Officer (our Principal Financial and Accounting Officer), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2017, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified in the “Risk Factors” section of our Registration Statement on Form S-1 (File No. 333-215027).

Our Chief Executive Officer and Chief Financial Officer do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officer has determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Controls Over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings.

Not Applicable.

Item 1.A.

Risk Factors.

See the section of our prospectus entitled “Risk Factors” beginning at page 13 of the Form S-1 filed with the SEC on May 5, 2017.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

Exhibit No.		Description of Exhibit

31.1		Section 302 Certification by Chief Executive Officer

31.2		Section 302 Certification by Chief Financial Officer

32.1		Section 906 Certification by Chief Executive Officer

32.2		Section 906 Certification by Chief Financial Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SHUTTLE PHARMACEUTICALS, INC.

Dated: August 14, 2017	By:	/s/ Anatoly Dritschilo
		Anatoly Dritschilo, Chief Executive Officer
		(Principal Executive Officer)

Dated: August 14, 2017	By:	/s/ Peter Dritschilo
		Peter Dritschilo, Chief Financial Officer
		(Principal Financial and Accounting Officer)

Shuttle Pharmaceuticals, Inc. 10-Q